Roche to Build R&D Center in China

Roche (RHBBY.PK) will build a second R&D center in China, spending $100 million to create the first fully functional China clinical drug R&D center that is owned by a multinational pharmaceutical company.

Until now, Roche, like many other big pharmas, has had an R&D emplacement that specializes in specific areas of the entire R&D development path. Other tasks, such as experiment design, are performed outside of China.

Combined with its present facility, the new R&D center will allow Roche to bring a new drug candidate to China, leaving the center responsible for all the work necessary to take the candidate completely through the regulatory process. This includes both experiment design, and statistical analysis. Roche China R&D will be self-sufficient.

Initially, Roche China will focus on oncology and metabolic drugs. Roche expects the number of its R&D employees to double next year from its present headcount of 80.

A report of this new center appeared in the China Business News, and was carried on the GBInformation website.

Check our this link for our other stories on Roche.

Disclosure: None.

Comments

[Chuck]

Wow, now they get to pay ultra low wages to get Chinese factory workers to take trial drugs, and see how many keel over.

I guess after all the lead they put in our toys, turn about is fair play?